These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats. Schwienteck KL; Faunce KE; Rice KC; Obeng S; Zhang Y; Blough BE; Grim TW; Negus SS; Banks ML Neuropharmacology; 2019 May; 150():200-209. PubMed ID: 30660628 [TBL] [Abstract][Full Text] [Related]
23. Pharmacological Characterization of Dezocine, a Potent Analgesic Acting as a κ Partial Agonist and μ Partial Agonist. Wang YH; Chai JR; Xu XJ; Ye RF; Zan GY; Liu GY; Long JD; Ma Y; Huang X; Xiao ZC; Dong H; Wang YJ Sci Rep; 2018 Sep; 8(1):14087. PubMed ID: 30237513 [TBL] [Abstract][Full Text] [Related]
24. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Traynor JR; Nahorski SR Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747 [TBL] [Abstract][Full Text] [Related]
25. Apparent thermodynamic parameters of ligand binding to the cloned rat mu-opioid receptor. Li JG; Raffa RB; Cheung P; Tzeng TB; Liu-Chen LY Eur J Pharmacol; 1998 Aug; 354(2-3):227-37. PubMed ID: 9754924 [TBL] [Abstract][Full Text] [Related]
26. Opioid regulation of the mouse delta-opioid receptor expressed in human embryonic kidney 293 cells. Bot G; Blake AD; Li S; Reisine T Mol Pharmacol; 1997 Aug; 52(2):272-81. PubMed ID: 9271350 [TBL] [Abstract][Full Text] [Related]
27. Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse. Mizoguchi H; Wu HE; Narita M; Hall FS; Sora I; Uhl GR; Nagase H; Tseng LF Neuroscience; 2002; 115(3):715-21. PubMed ID: 12435410 [TBL] [Abstract][Full Text] [Related]
28. [(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord. Madia PA; Navani DM; Yoburn BC Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651 [TBL] [Abstract][Full Text] [Related]
29. Opioid antagonist-induced receptor upregulation: effects of concurrent agonist administration. Yoburn BC; Duttaroy A; Shah S; Davis T Brain Res Bull; 1994; 33(2):237-40. PubMed ID: 8275346 [TBL] [Abstract][Full Text] [Related]
30. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes. Lester PA; Traynor JR Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205 [TBL] [Abstract][Full Text] [Related]
31. A6V polymorphism of the human μ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro. Knapman A; Santiago M; Connor M Br J Pharmacol; 2015 May; 172(9):2258-72. PubMed ID: 25521224 [TBL] [Abstract][Full Text] [Related]
32. Selectivity of mu-opioid receptor determined by interfacial residues near third extracellular loop. Bonner G; Meng F; Akil H Eur J Pharmacol; 2000 Sep; 403(1-2):37-44. PubMed ID: 10969141 [TBL] [Abstract][Full Text] [Related]
33. A pharmacological comparison of the cloned frog and human mu opioid receptors reveals differences in opioid affinity and function. Brasel CM; Sawyer GW; Stevens CW Eur J Pharmacol; 2008 Dec; 599(1-3):36-43. PubMed ID: 18930720 [TBL] [Abstract][Full Text] [Related]
34. Internalization and recycling of human mu opioid receptors expressed in Sf9 insect cells. Chen LE; Gao C; Chen J; Xu XJ; Zhou DH; Chi ZQ Life Sci; 2003 May; 73(1):115-28. PubMed ID: 12726892 [TBL] [Abstract][Full Text] [Related]
35. Stereochemical requirements for pseudoirreversible inhibition of opioid mu receptor binding by the 3-methylfentanyl congeners, RTI-46144 and its enantiomers: evidence for different binding domains. Ni Q; Xu H; Partilla JS; Stark PA; Carroll FI; Brine GA; Rothman RB Synapse; 1993 Dec; 15(4):296-306. PubMed ID: 8153877 [TBL] [Abstract][Full Text] [Related]
36. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay. Sterious SN; Walker EA J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605 [TBL] [Abstract][Full Text] [Related]
37. A conserved arginine in the distal third intracellular loop of the mu-opioid receptor is required for G protein activation. Wang HL J Neurochem; 1999 Mar; 72(3):1307-14. PubMed ID: 10037504 [TBL] [Abstract][Full Text] [Related]
38. Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys. Cornelissen JC; Obeng S; Rice KC; Zhang Y; Negus SS; Banks ML J Pharmacol Exp Ther; 2018 Apr; 365(1):37-47. PubMed ID: 29330156 [TBL] [Abstract][Full Text] [Related]
39. The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Chen JC; Smith ER; Cahill M; Cohen R; Fishman JB Life Sci; 1993; 52(4):389-96. PubMed ID: 8093631 [TBL] [Abstract][Full Text] [Related]
40. Differences in the characteristics of tolerance to μ-opioid receptor agonists in the colon from wild type and β-arrestin2 knockout mice. Maguma HT; Dewey WL; Akbarali HI Eur J Pharmacol; 2012 Jun; 685(1-3):133-40. PubMed ID: 22521552 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]